The number of FoxP3 regulatory T cells in the circulation may be a predictive biomarker for kidney transplant recipients: A multistage systematic review.

Détails

ID Serval
serval:BIB_87F4826FC3D2
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
The number of FoxP3 regulatory T cells in the circulation may be a predictive biomarker for kidney transplant recipients: A multistage systematic review.
Périodique
International immunopharmacology
Auteur(s)
Herrera-Gómez F., Del Aguila W., Tejero-Pedregosa A., Adler M., Padilla-Berdugo R., Maurtua-Briseño-Meiggs Á., Pascual J., Pascual M., San Segundo D., Heidt S., Álvarez F.J., Ochoa-Sangrador C., Lambert C.
ISSN
1878-1705 (Electronic)
ISSN-L
1567-5769
Statut éditorial
Publié
Date de publication
12/2018
Peer-reviewed
Oui
Volume
65
Pages
483-492
Langue
anglais
Notes
Publication types: Journal Article ; Systematic Review
Publication Status: ppublish
Résumé
The kinetics of the FoxP3 regulatory T-cell (Treg) population in kidney transplant recipients (KTR) are related to the clinical effect of immunosuppression based on mammalian Target Of Rapamycin inhibitors (mTORi) with/without belatacept (predictive biomarker).
A multistage systematic review of published and unpublished literature is presented [registration IDs in the International Prospective Register of Systematic Reviews (PROSPERO): CRD42017057570, CRD42018085019, CRD42018084941, CRD42018085186]. A multidisciplinary supervision mechanism for contextualizing of search findings was required. The peripheral blood immune cell phenotypes encompassing all regulatory cells in KTRs were assessed in order to suggest new markers of acute rejection-associated acute allograft dysfunction (AR/AAD) events in KTRs treated with mTORi alone or combined to belatacept. Quantitative estimates and evaluation of the body of evidence are provided.
An increase in Tregs and other regulatory cell types in the circulation in KTRs under mTORi with/without belatacept were observed. Patients with increased Tregs presented a low frequency of AR/AAD events compared to those in which the number of Tregs remained unchanged or even diminished [Odds Ratio (OR)/95% confidence interval (95% CI)/I <sup>2</sup> /number of studies (n): 0.31/0.10-0.93/0%/6]. Nevertheless, there are too few trials to consider Tregs in the circulation as a predictive biomarker. Inadequate reporting prevents appreciating clinical relevance in such studies.
Despite advances, clinical qualification of potential predictive biomarkers continues to be difficult. Clinical evidence on Tregs in KTRs needs to be enlarged. Biomarkers should be able to evaluate the effect of medicines targeted to specific patient populations.
Mots-clé
Animals, Biomarkers, Blood Circulation, Clinical Trials as Topic, Forkhead Transcription Factors/metabolism, Graft Rejection/diagnosis, Graft Rejection/immunology, Graft Survival, Humans, Kidney Transplantation, Prognosis, T-Lymphocytes, Regulatory/immunology, Transplantation, Homologous, Kidney transplantation, Pharmacological, Regulatory, T-lymphocytes, Transplantation tolerance
Pubmed
Web of science
Création de la notice
12/11/2018 14:55
Dernière modification de la notice
20/08/2019 14:47
Données d'usage